CRA-2059

• UNSPSC Description:

  CRA-2059 is a highly specific and selective tryptase inhibitor, with a Ki of 620 pM for recombinant human tryptase-β (rHTβ)[1][2].

• Target Antigen:

  Ser/Thr Protease

• Type:

  Reference compound

• Related Pathways:

  Metabolic Enzyme/Protease

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/cra-2059.html

• Solubility:

  10 mM in DMSO

• Smiles:

  NC(NC1=CC=C(CNC(N2CCN(C(O[C@@H]3COC4[C@H](OC(N5CCN(C(NCC6=CC=C(NC(N)=N)C=C6)=O)CC5)=O)COC34)=O)CC2)=O)C=C1)=N

• Molecular Weight:

  750.80

• References & Citations:

  [1]Tremaine WJ, et al. Treatment of mildly to moderately active ulcerative colitis with a tryptase inhibitor (APC 2059): an open-label pilot study. Aliment Pharmacol Ther. 2002;16(3):407-413.|[2]Selwood T, et al. Potent bivalent inhibition of human tryptase-beta by a synthetic inhibitor. Biol Chem. 2003;384(12):1605-1611.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  256649-36-2